Literature DB >> 20110921

Does serum osteoprotegerin level relate to fragility fracture in elderly women with low vitamin D status?

Grazyna Sypniewska1, Izabela Sobanska, Agnieszka Pater, Kornelia Kedziora-Kornatowska, Wieslaw Nowacki.   

Abstract

BACKGROUND: Increased osteoprotegerin (OPG) with elevated bone turnover is supposed to be a homeostatic mechanism limiting bone loss. MATERIAL/
METHODS: Whether osteoprotegerin relates to low-energy fracture in elderly women was investigated by analyzing the relationship between OPG and bone turnover. Sixty-nine women with a first fragility hip fracture participated. The reference group consisted of 23 age-matched women. Serum calcium, 25-OHD3, parathormone, osteocalcin (OC), cross-linked C-terminal telopeptides (CTX-I), tartrate-resistant acid phosphatase (TRAP5b), and osteoprotegerin were assayed immediately post-fracture.
RESULTS: In both groups, median vitamin D and calcium concentrations were in the low reference range, CTX-I were moderately elevated, and TRAP5b activity and parathormone were within the reference range. Significantly lower osteocalcin, a trend to higher OPG, and an inverse correlation between OPG and osteocalcin was found in the fracture group. The distribution of fracture was related to osteocalcin and OPG concentrations: the lower the OC level, the higher the number of women with fracture at increasing OPG concentrations. A relative imbalance between bone formation and resorption was found in the fracture group. The lowest osteocalcin level (Q1) was observed only and vitamin 25-OHD3 insufficiency predominantly in the fracture group and higher OPG, TRAP5b, and elevated CTX-I concentrations (Q3) were found more often or predominantly in this group.
CONCLUSIONS: The data demonstrate a relative imbalance between bone formation and resorption associated with fragility fracture in elderly women with low vitamin D status. The authors suggest that compensatory elevation of serum OPG, particularly with reduced bone formation, is insufficient to limit bone loss leading to fracture.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20110921

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  9 in total

1.  Osteoprotegerin and fractures in men and women with chronic kidney disease.

Authors:  Sarah L West; Charmaine E Lok; Sophie A Jamal
Journal:  J Bone Miner Metab       Date:  2014-07       Impact factor: 2.626

2.  Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.

Authors:  P Wanby; R Nobin; S-P Von; L Brudin; M Carlsson
Journal:  J Endocrinol Invest       Date:  2016-02-05       Impact factor: 4.256

3.  Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer.

Authors:  Drew R Oostra; Maryam B Lustberg; Raquel E Reinbolt; Xueliang Pan; Robert Wesolowski; Charles L Shapiro
Journal:  Mol Cell Endocrinol       Date:  2015-01-06       Impact factor: 4.102

4.  Multifactorial analysis of risk factors for reduced bone mineral density among postmenopausal women.

Authors:  Grażyna Bączyk; Tomasz Opala; Paweł Kleka; Marek Chuchracki
Journal:  Arch Med Sci       Date:  2012-05-09       Impact factor: 3.318

5.  Reduced serum concentrations of 25-hydroxy vitamin D in Egyptian patients with systemic lupus erythematosus: relation to disease activity.

Authors:  Rasha T Hamza; Khaled S Awwad; Mohamed K Ali; Amira I Hamed
Journal:  Med Sci Monit       Date:  2011-12

Review 6.  Modulation of vitamin D signaling is a potential therapeutic target to lower cardiovascular risk in chronic kidney disease.

Authors:  Peng Hu; Bo Hu; Jing Wang; Ling Lu; Yuan Han Qin
Journal:  Med Sci Monit       Date:  2011-06

7.  The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy.

Authors:  Ewa Sewerynek; Hanna Horst-Sikorska; Wioletta Stępień-Kłos; Agnieszka Antkowiak; Małgorzata Janik; Karol Cieślak; Michalina Marcinkowska; Agnieszka Cegłowska; Michał Stuss
Journal:  Arch Med Sci       Date:  2013-04-22       Impact factor: 3.318

8.  PvuII and XbaI polymorphisms of estrogen receptor-α and the results of estroprogestagen therapy in girls with functional hypothalamic amenorrhea - preliminary study.

Authors:  Elżbieta Sowińska-Przepiera; Anhelli Syrenicz; Zbigniew Friebe; Grażyna Jarząbek-Bielecka; Kornel Chełstowski
Journal:  Arch Med Sci       Date:  2012-10-16       Impact factor: 3.318

9.  Circulating vascular endothelial growth factor concentrations in patients with postmenopausal osteoporosis.

Authors:  Kazim Senel; Tuba Baykal; Buminhan Seferoglu; Elif Umay Altas; Fatih Baygutalp; Mahir Ugur; Ahmet Kiziltunc
Journal:  Arch Med Sci       Date:  2013-08-08       Impact factor: 3.318

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.